Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zoster vaccine recombinant, adjuvanted
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Zoster vaccine recombinant, adjuvanted is a non-live, recombinant subunit vaccine indicated for the prevention of herpes zoster (shingles) in adults. It contains varicella-zoster virus glycoprotein E (gE) as the antigen and uses the AS01B adjuvant system to enhance immune response. The mechanism of action involves stimulating a strong cell-mediated and humoral immune response against varicella-zoster virus by presenting gE with an immunostimulatory adjuvant. This results in robust protection against reactivation of latent VZV infection that causes shingles. Developed primarily for adults aged 50 years and older, its indication was expanded to include adults aged 18 years and older who are or will be at increased risk due to immunodeficiency or immunosuppression[2][3][6][7]. The product is administered intramuscularly as a two-dose series.
- Brand names
- Shingrix
- Other names
- recombinant zoster vaccineRZVherpes zoster vaccine non-live recombinant adjuvanted
02
Targets
gE (VZV glycoprotein E)
Beyond the preview
Go deeper on zoster vaccine recombinant, adjuvanted.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zoster vaccine recombinant, adjuvanted.